Insiders who bought US$126.0k worth of 60 Degrees Pharmaceuticals, Inc.'s (NASDAQ:SXTP) stock at an average buy price of US$1.27 over the last year may be disappointed by the recent 24% decrease ...

WASHINGTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for ...

Insiders who bought US$126.0k worth of 60 Degrees Pharmaceuticals, Inc.'s (NASDAQ:SXTP) stock at an average buy price of US$1.27 over the last year may be disappointed by the recent 24% decrease in ...

60 Degrees Pharmaceuticals (SXTP) has entered into definitive agreements for the purchase and sale of an aggregate of 1,503,500 shares of its common stock at a purchase price of 71.5c per share in ...

WASHINGTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious ...

Enrollment expected to commence Q3 2025. WASHINGTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on ...

Create an account or log in to save stories. We made it. I’m 99.9 percent sure Tuesday morning’s low temperature of minus 19 degrees at Minneapolis-St. Paul International Airport will stand as ...

60 Degrees Pharmaceuticals, Inc. announced the approval of an Investigational Review Board (IRB) for a Phase II clinical study aimed at evaluating the efficacy and safety of tafenoquine ...